Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NeuroDerm Ltd NDRM

Healthcare Biotechnology
"NeuroDerm Ltd is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system diseases, including Parkinson's disease as well as other CNS diseases."

Recent & Breaking News (NDAQ:NDRM)

NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017

GlobeNewswire March 21, 2017

20 Biggest Mid-Day Losers For Tuesday

Benzinga.com  March 7, 2017

NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting

GlobeNewswire March 1, 2017

NeuroDerm CEO to Present at Upcoming Investor Conferences

GlobeNewswire February 27, 2017

NeuroDerm Announces Extraordinary General Meeting of Shareholders

GlobeNewswire January 26, 2017

NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017

GlobeNewswire January 3, 2017

NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire December 22, 2016

NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease

GlobeNewswire December 22, 2016

NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares

GlobeNewswire December 7, 2016

NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares

GlobeNewswire December 6, 2016

Mid-Afternoon Market Update: NeuroDerm Surges Following Meeting With FDA; Cerecor Shares Slide

Benzinga.com  December 5, 2016

NeuroDerm Likely Boosted By Short Squeeze Following FDA News

Benzinga.com  December 5, 2016

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  December 5, 2016

Mid-Day Market Update: NASDAQ Up 1%; Ocean Power Technologies Shares Spike Higher

Benzinga.com  December 5, 2016

Mid-Morning Market Update: Markets Open Higher; Consolidated Communications to Acquire FairPoint Communications

Benzinga.com  December 5, 2016

NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development

GlobeNewswire December 5, 2016

NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine

GlobeNewswire December 2, 2016

NeuroDerm Announces Third Quarter 2016 Financial Results

GlobeNewswire November 10, 2016

NeuroDerm CEO to Present at Upcoming Investor Conferences

GlobeNewswire November 3, 2016

NeuroDerm to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016

GlobeNewswire November 1, 2016